NYSEAMERICAN:OGEN Oragenics (OGEN) Stock Price, News & Analysis $0.62 +0.02 (+2.84%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About Oragenics Stock (NYSEAMERICAN:OGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oragenics alerts:Sign Up Key Stats Today's Range$0.60▼$0.6450-Day Range$0.50▼$0.7552-Week Range$0.50▼$9.60Volume238,042 shsAverage Volume48,084 shsMarket Capitalization$2.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oragenics, Inc. is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics. The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications. Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN. Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization. AI Generated. May Contain Errors. Read More Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGEN Stock News HeadlinesOragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21May 19, 2026 | finance.yahoo.comOragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21May 19, 2026 | globenewswire.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 2 at 1:00 AM | Porter & Company (Ad)ORAGENICS PROVIDES INVESTOR UPDATEMay 18, 2026 | globenewswire.comOragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic InflammationMay 7, 2026 | globenewswire.comOragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.May 5, 2026 | globenewswire.comOragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryApril 20, 2026 | finance.yahoo.comOragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryApril 13, 2026 | globenewswire.comSee More Headlines OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed this year? Oragenics' stock was trading at $0.78 at the beginning of 2026. Since then, OGEN stock has decreased by 22.4% and is now trading at $0.6050. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its quarterly earnings results on Friday, May, 8th. The company reported ($0.51) earnings per share (EPS) for the quarter. When did Oragenics' stock split? Oragenics's stock reverse split before market open on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Jaguar Animal Health (JAGX), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and Amarin (AMRN). Company Calendar Last Earnings5/08/2026Today6/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (28m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 OGEN's financial health is in the Red zone, according to TradeSmith. OGEN has been in this zone for over 28 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:OGEN Previous SymbolNYSE:OGEN CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-177.32% Return on Assets-121.29% Debt Debt-to-Equity RatioN/A Current Ratio5.73 Quick Ratio5.73 Sales & Book Value Annual Sales$40 thousand Price / Sales70.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.32Miscellaneous Outstanding Shares4,510,000Free Float3,786,000Market Cap$2.81 million OptionableN/A Beta1.27 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSEAMERICAN:OGEN) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersThe Rare Earth Shift Few Saw ComingRare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - ye...i2i Marketing Group, LLC | SponsoredFREE OFFER – DOWNLOAD NOWTom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what ...DTI Trader | SponsoredOver 90 Years Later, Trump May Finally Reverse 1933's Gold HeistTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...American Hartford Gold | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredFree: The Crypto Summit That Could Change Your Life27 of crypto's most successful insiders are breaking their silence in an emergency summit. The architects o...Crypto 101 Media | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayOctober 14th, 2025, CNBC quietly published an interview with BlackRock's CEO, who went on live television and ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
